BridgeBio Pharma, Inc. BBIO
BridgeBio Pharma, Inc. is a commercial-stage, multi-product biopharmaceutical company organized around a portfolio operating model to discover, develop, and deliver medicines for patients with genetic diseases. We seek to translate advances in genetic science into therapies for patient populations with significant unmet medical needs.
Since our founding 10 years ago, we have advanced multiple programs from discovery through regulatory approval and commercialization. To date, more than 8,500 patients have been treated with our approved medicines, and we have obtained U.S. Food and Drug Administration (the "FDA") approval for three products. We believe our decentralized hub and spoke model enables us to achieve clinical proof-of-concept with speed and efficiency, demonstrated by an average investment per program of less than $40.0 million to proof-of-concept data and less than $10.0 million to reach Investigational New Drug ("IND") submission. This efficiency allows us to work on a broad range of scientifically compelling therapies, including programs for underserved conditions which more traditional biopharmaceutical models might leave on the shelf but we believe can be developed on a Net Present Value ("NPV")-positive basis in our portfolio.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $502.1M | $221.9M | $9.3M | $77.6M | $69.7M | $8.2M | $40.6M | — | — | — |
| Cost of revenue | $21.0M | $3.9M | $2.4M | $3.4M | $3.1M | — | — | — | — | — |
| Gross profit | $481.1M | $218.0M | $6.9M | $74.2M | $66.6M | — | — | — | — | — |
| R&D | $452.0M | $506.5M | $455.7M | $399.5M | $451.0M | $337.0M | $209.9M | $140.1M | $30.6M | — |
| SG&A | $531.2M | $288.9M | $150.6M | $143.2M | $192.2M | $145.7M | $94.4M | $43.6M | $13.3M | — |
| Total operating expenses | $1.03B | $814.9M | $616.7M | $589.9M | $646.3M | $482.7M | $306.8M | $183.7M | $43.9M | — |
| Operating income | -$523.4M | -$593.0M | -$607.4M | -$512.2M | -$576.6M | -$474.5M | -$266.2M | -$183.7M | -$43.9M | — |
| Interest expense | $53.1M | $91.0M | $81.3M | $80.4M | $46.8M | $36.7M | $8.8M | $2.5M | $13.0K | — |
| Pre-tax income | -$732.5M | -$542.2M | -$653.3M | -$484.7M | — | $505.5M | $288.6M | $169.5M | $43.8M | — |
| Income tax | $435.0K | $1.2M | $0 | $0 | — | — | — | — | — | — |
| Net income | -$732.9M | -$543.3M | -$653.3M | -$484.6M | -$586.5M | -$505.5M | -$288.6M | -$169.5M | -$43.8M | — |
| EPS, basic | -3.78 | -2.88 | -3.95 | -3.26 | -3.90 | -3.80 | — | — | — | — |
| EPS, diluted | -3.78 | -2.88 | -3.95 | -3.26 | -3.90 | -3.80 | -2.48 | -2.12 | -1.00 | — |
| Shares, diluted (wtd. avg.) | $191.5M | $186.1M | $162.8M | $147.5M | $144.4M | $118.0M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $570.1M | $681.1M | $375.9M | $376.7M | $393.8M | $356.1M | $363.8M | $436.1M | $92.0M | — |
| Short-term investments | $17.4M | $0 | $0 | $51.6M | $393.7M | $251.0M | $182.2M | — | — | — |
| Receivables | $139.4M | $4.7M | $1.8M | — | — | — | — | — | — | — |
| Inventory | $26.8M | $0 | — | — | — | — | — | — | — | — |
| Total current assets | $797.7M | $720.7M | $477.6M | $548.9M | $888.9M | $642.8M | $568.6M | $445.2M | — | — |
| Property, plant and equipment | $5.4M | $7.0M | $11.8M | $14.6M | $30.1M | $20.3M | $5.6M | $1.6M | — | — |
| Other intangibles | $28.1M | $23.9M | $26.3M | $28.7M | $44.9M | $0 | — | — | — | — |
| Total assets | $936.0M | $919.3M | $546.4M | $623.0M | $1.01B | $703.6M | $631.7M | $464.9M | — | — |
| Accounts payable | $36.2M | $9.6M | $10.7M | $11.6M | $11.9M | $8.9M | $8.9M | $13.5M | — | — |
| Short-term debt | — | — | — | — | — | $1.5M | — | — | — | — |
| Total current liabilities | $288.0M | $154.4M | $143.8M | $121.4M | $135.1M | $95.6M | $60.4M | $32.6M | — | — |
| Long-term debt | $2.01B | $437.3M | $446.4M | $431.0M | $430.8M | $92.4M | $91.8M | $54.5M | — | — |
| Total liabilities | $3.01B | $2.38B | $1.89B | $1.87B | $1.88B | $595.7M | $155.7M | $87.6M | — | — |
| Retained earnings | -$3.82B | -$3.10B | -$2.56B | -$1.92B | -$1.44B | -$888.8M | -$440.0M | -$179.4M | -$48.7M | -$18.1M |
| Total equity | -$2.09B | -$1.47B | -$1.34B | -$1.24B | -$867.0M | $106.3M | $473.7M | $377.2M | $88.3M | $14.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$445.9M | -$520.7M | -$527.7M | -$419.5M | -$497.9M | -$399.7M | -$253.6M | -$136.6M | -$40.5M | — |
| Depreciation and amortisation | $5.4M | $6.1M | $6.5M | $6.8M | $5.8M | $1.5M | $859.0K | — | — | — |
| Stock-based compensation | $133.0M | $95.8M | $108.7M | $91.6M | $99.5M | $58.5M | $21.4M | $6.1M | $1.8M | — |
| Capital expenditure | $1.1M | $933.0K | $1.3M | $4.8M | $13.2M | $7.5M | $2.6M | $2.2M | $464.0K | — |
| Investing cash flow | -$24.5M | $60.8M | $54.0M | $453.1M | -$200.8M | -$53.0M | -$217.3M | -$21.0M | -$464.0K | — |
| Financing cash flow | $359.3M | $748.5M | $451.5M | -$13.1M | $736.4M | $447.2M | $398.8M | $501.5M | $113.0M | — |
| Dividends paid | — | — | — | — | — | — | $997.0K | — | $1.2M | — |
| Buybacks | $48.3M | $0 | $0 | $0 | $200.0M | $75.0M | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-016723.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |